Goldman SachsGSPAST TOP PICKSep 07, 2017Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
(A Top Pick Aug 8/16. Up 34.44%.) This has something unique. While almost every other major global investment bank has reduced its trading exposure, this one hasn’t. Therefore, competition has fallen off dramatically. Margins in trading and related businesses, are expanding dramatically. The only major US global bank that has fewer shares outstanding than they did before the financial crisis. This is still a buy.